HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

First experience using peptide receptor radionuclide therapy in a patient with urothelial carcinoma.

Abstract
A 78-year-old man with urothelial carcinoma metastasis after surgical resection of the right kidney, part of the ureter, and urinary bladder in May 2003 and 3 cycles of chemotherapy with cisplatin-gemcitabine was referred for peptide receptor radionuclide therapy (PRRT). Somatostatin-receptor profile was assessed by 68Ga-labeled lanreotide PET, and PRRT was performed using 3738 MBq (101 mCi) of 90Y-DOTA-lanreotide. Because of adequate PRRT response confirmed with MRI and 18F-FDG PET, surgical resection of the solitary cervical metastasis was feasible. Treatment was well tolerated, and the patient remains in complete remission from his urothelial carcinoma.
AuthorsDaniel Putzer, Michael Gabriel, Rupert Prommegger, Dorota Kendler, Irene Johanna Virgolini
JournalClinical nuclear medicine (Clin Nucl Med) Vol. 38 Issue 10 Pg. e404-6 (Oct 2013) ISSN: 1536-0229 [Electronic] United States
PMID23579972 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Peptides, Cyclic
  • Receptors, Peptide
  • lanreotide
  • Somatostatin
Topics
  • Aged
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Peptides, Cyclic (therapeutic use)
  • Positron-Emission Tomography
  • Receptors, Peptide (therapeutic use)
  • Somatostatin (analogs & derivatives, therapeutic use)
  • Treatment Outcome
  • Urinary Bladder Neoplasms (diagnostic imaging, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: